Weapon-Maker Axon Shares Rise In Monday Pre-Market: What's Going On?
Weapon-Maker Axon Shares Rise In Monday Pre-Market: What's Going On?
The three most recent analyst ratings came from Axon Enterprise Inc (NASDAQ:AXON) experienced a notable 2.81% increase in pre-market trading on Monday. This surge follows the company's inclusion in the prestigious Nasdaq-100 Index over the weekend.
Axon Enterprise Inc (納斯達克:AXON) 在週一美股盤前交易中上漲了2.81%。這一增長是由於該公司在週末被納入了著名的納斯達克100指數。
The Nasdaq announced the results of its annual reconstitution of the Nasdaq-100 Index on Saturday, which saw Axon joining the ranks. This index, which was established in January 1985, serves as a crucial benchmark for non-financial companies listed on the Nasdaq. It supports a variety of financial products, including options, futures, and funds. Alongside Axon, Palantir and MicroStrategy were also added to the reorganized list.
納斯達克於星期六宣佈了其年度重組納斯達克-100 指數的結果，Axon 成爲新成員。該指數成立於1985年1月，是納斯達克上市非金融公司的重要基準。它支持多種金融產品，包括期權、期貨和所有基金類型。除了Axon外，Palantir 和 MicroStrategy 也被納入了重組後的名單。
According to Benzinga Pro, the weapon maker has a consensus price target of $424.76, based on evaluations from 17 analysts. The highest target of $800 was set by Baird on December 6, 2024, while the lowest was $130, issued by Needham on May 11, 2022.
根據Benzinga Pro的數據，這家武器製造商的共識目標價爲424.76美元，基於17位分析師的評估。最高目標價爲800美元，由Baird在2024年12月6日設定，而最低目標價爲130美元，由Needham在2022年5月11日發佈。
The three most recent analyst ratings came from Baird, Morgan Stanley, and Northland Capital Markets, dated Dec. 6, Dec. 3, and Nov. 11, respectively. These ratings suggest an average price target of $683.33, indicating a potential 3.07% upside for Axon Enterprise Inc.
最近的三條分析師評級來自Baird、摩根士丹利和北蘭資本市場，日期分別爲12月6日、12月3日和11月11日。這些評級建議的平均目標價爲683.33美元，顯示Axon Enterprise Inc.有潛在的3.07%的上漲空間。
- Dogecoin's Fate Tied To Bitcoin, Says Crypto Analyst: 'Sit Back And Wait'
- 狗狗幣的命運與比特幣息息相關，分析師表示：『坐等觀望』
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.
免責聲明：此內容部分由Benzinga Neuro生成，並由Benzinga編輯審核和發佈。
Image via Shutterstock
圖片來源：shutterstock
譯文內容由第三人軟體翻譯。
